We, at the Innovation and Value Initiative, are deeply appreciative and excited about the growing number of members who share our commitment to advancing the science of value assessment. As part of our Value Source Blog, we are introducing our Member Spotlight series, where we talk with IVI members about the future of value assessment [...]
Author: Jennifer Bright, MPA, Executive Director, IVI For decades, we've known that untreated or poorly treated Major Depressive Disorder (MDD) is an enormous burden on individual patients, our health care system, and our society. Despite having this knowledge, there is much work to do in order to support and optimize cost-effective care for patients suffering [...]
First of Its Kind Depression Model to be Informed by Input from Diverse Advisory Group September 9, 2020 — Alexandria, VA — The Innovation and Value Initiative (IVI) — a non-profit organization dedicated to advancing the science, practice, and use of value assessment in healthcare — today announced a multi-year initiative to build and test [...]
IVI and the University of Maryland Pharmacy School’s PAVE Center Partner on Patient-Centered Value Assessment
In an article in The Patient, IVI and the Patient-Driven Values in Healthcare Evaluation (PAVE) Center at the University of Maryland School of Pharmacy describe how they develop methods and models that make patient-centered value assessment both scientifically feasible and relevant to real-world decisions across the range of stakeholders. Read the full article here.
Second Webinar in the ISPOR-IVI Series Explores Whether Value Assessments are Up to the Task in the Age of COVID-19
The second part of a five-part webinar series examining value assessment in the COVID-19 era hosted by ISPOR and the Innovation and Value Initiative (IVI) will explore whether the methods on which health economists have relied are up to task or in need of improvement for the pandemic era. Moderated by Lou Garrison, PhD (University [...]
Author: Jennifer Bright, MPA Everyone hopes for a COVID vaccine so our lives can return to normal. Yet, we know that even if clinical trials prove a vaccine's effectiveness, our society will still have to endure a long process of distribution. I'm personally willing to wait for a vaccine for healthcare workers, the elderly, and [...]
IVI is pleased to share our Annual Report that documents the transition of our organization to an independent, 501c(3) organization, describes our membership and patient engagement strategies, and offers highlights and learnings from research and convening activities over the past 18 months.
In an interview with Dr. William Seeds in Authority Magazine, Jennifer Bright talks about her own journey to IVI, what drives her to improve value assessment, and why collaboration is paramount for success. Read the full interview here.
In a commentary in AJMC, IVI examines how multi-criteria decision analysis has the potential to better understand and assess value for innovative cell and gene therapies which are transforming the lives of patients living with serious diseases. Read the full article here.
Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and take an average of 15 years – to develop one therapy. For the 30% of children diagnosed with a rare [...]